Orient Europharma Co., Ltd. AI Stock Analysis
Orient Europharma Co., Ltd. (4120) AI Stock Analysis
Orient Europharma Co., Ltd.
(TPEx:4120)
Orient Europharma scores poorly, driven primarily by weak financial performance: declining revenue, a widening net loss of roughly NT$567m, and sustained cash burn with free cash flow near -NT$472m. The main offset is a substantially repaired balance sheet, where debt-to-equity fell from 1.38 to 0.52 and equity now funds over half of assets, providing a cushion to absorb further losses. Technicals add to the caution, with the price below all key moving averages and a negative MACD, though oversold RSI and Stochastic readings leave room for a short-term bounce. Valuation offers little clarity — earnings are negative and the 9.46% dividend yield looks hard to sustain against negative cash generation. A turn in the score would require evidence of revenue growth, tighter operating costs, and a return to positive cash flow.
Orient Europharma Co., Ltd. (4120) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 3.85B
- Dividend Yield
- 9.02%
- Average Volume (3M)
- 22.38K
- Price to Earnings (P/E)
- -6.7
- Beta (1Y)
- 0.14
- Revenue Growth
- 3.77%
- EPS Growth
- -78.32%
- Country
- TW
- Employees
- 339
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Orient Europharma Co., Ltd. Business Overview & Revenue Model
Company Description
Orient EuroPharma Co., Ltd. (OEP) operates as a global pharmaceutical enterprise, engaged in the development and production of various medications. Its portfolio of prescription pharmaceuticals encompasses treatments for a wide array of conditions, s...
Orient Europharma Co., Ltd. Financial Statement Overview
Summary
Fundamentals are weak overall. The income statement (score 28) shows multi-year revenue erosion from NT$5.38bn in 2020 to roughly NT$4.6bn, an operating loss of about NT$311m and a net loss widening to roughly NT$567m, with earnings swinging erratically between profit and loss. Cash flow (score 20) is the biggest concern: operating cash flow deteriorated to about -NT$299m and free cash flow to about -NT$472m, with positive operating cash in only two of the last six years. The balance sheet (score 58) is the clear bright spot — equity more than doubled to NT$6.29bn, debt was cut to NT$3.27bn and debt-to-equity improved sharply from 1.38 to 0.52 — but this cushion was funded by capital raising rather than earned, and ROE remains negative at about -9%. Stable gross margins near 46% confirm product-level pricing power, yet the cost structure continues to consume both profit and cash.
Income Statement
28NegativeBalance Sheet
58NeutralCash Flow
20Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.65B | 4.60B | 4.39B | 4.59B | 4.73B | 4.77B |
| Gross Profit | 2.17B | 2.10B | 2.07B | 2.15B | 2.03B | 2.15B |
| EBITDA | -145.21M | -121.76M | 183.90M | 596.88M | -34.15M | 133.32M |
| Net Income | -538.56M | -567.39M | -283.93M | 143.94M | -310.80M | 120.17M |
Balance Sheet | ||||||
| Total Assets | 11.75B | 12.21B | 11.57B | 10.81B | 10.43B | 9.40B |
| Cash, Cash Equivalents and Short-Term Investments | 1.67B | 2.12B | 1.89B | 2.14B | 1.95B | 2.06B |
| Total Debt | 3.53B | 3.27B | 4.23B | 4.84B | 5.03B | 4.23B |
| Total Liabilities | 5.41B | 4.85B | 5.75B | 6.65B | 6.99B | 5.95B |
| Stockholders Equity | 5.23B | 6.29B | 5.16B | 3.51B | 2.93B | 2.94B |
Cash Flow | ||||||
| Free Cash Flow | -825.61M | -472.30M | -221.31M | 20.28M | -859.84M | -1.49B |
| Operating Cash Flow | -598.50M | -298.63M | -121.11M | 120.98M | -218.75M | 77.65M |
| Investing Cash Flow | 120.45M | 1.62B | 465.20M | 62.11M | -611.56M | -1.50B |
| Financing Cash Flow | -105.50M | -1.05B | -760.92M | -209.71M | 428.31M | 1.36B |
Orient Europharma Co., Ltd. Peers Comparison
Overall Rating
TW:177776.3Outperform
TW:178664Neutral- TW:412040Underperform
TW:687537Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:1777 | 76Outperform | TWD 3.34B | 9.97 | ― | 5.35% | -1.07% | 10.62% |
| TW:1786 | 64Neutral | TWD 3.89B | 21.40 | ― | 3.67% | -2.25% | -15.57% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:4120 | 40Underperform | TWD 3.85B | -6.67 | ― | 9.02% | 3.77% | -78.32% |
| TW:6875 | 37Underperform | TWD 3.24B | -9.12 | ― | ― | -69.26% | -24.53% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4120 | Orient Europharma Co., Ltd. | 44.35 | 2.18 | 5.18% | |
| TW:1777 | SYN-TECH Chemical & Pharmaceutical Co. Ltd. | 74.80 | 0.94 | 1.28% | |
| TW:1786 | SciVision Biotech Inc. | 52.00 | -20.15 | -27.93% | |
| TW:6634 | Sinew Pharma, Inc. | 57.20 | 16.70 | 41.23% | |
| TW:6875 | Pharmosa Biopharm Inc. | 25.05 | -24.60 | -49.55% | |
| TW:6885 | BRIM Biotechnology, Inc. | 26.85 | -3.00 | -10.05% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026